deltatrials
Completed PHASE4 NCT00049972

Major Depressive Disorder Study In Adults

An Open Label Study Assessing Paxil CR (Paroxetine CR) in Patients With Major Depressive Disorder Who Discontinued Treatment With Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability

Sponsor: GlaxoSmithKline

Conditions Major Depressive Disorder
Interventions paroxetine CR
Updated 7 times since 2017 Last updated: Sep 8, 2017 Started: Sep 30, 2002 Primary completion: Sep 30, 2003 Completion: Sep 30, 2003

A PHASE4 clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Oct 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Oct 2017 [monthly]

    Completed PHASE4

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States, Anaheim Hills, United States, Atlanta, United States, Bartlett, United States, Bellflower, United States, Birmingham, United States, Blackwood, United States, Boynton Beach, United States, Carrboro, United States, Cary, United States and 56 more location s